Effect of Study Probiotics on Body Fat Mass in Overweight and Obese Individuals Following Healthy Lifestyle Intervention

Exclusion Criteria

• •1. Diagnosed and pharmacologically-treated type 1 and type 2 diabetes (fasting blood glucose ≥ 7 mmol/l)
• •2. Use of medication/supplements for blood glucose control
• •3. Pharmacologically-treated (medication/supplements) hypertension or dyslipidemia
• •4. Cardiovascular disease, hypertensive retinopathy, left ventricular dysfunction, secondary hypertension, liver dysfunction/disease, kidney dysfunction/disease, dementia, thyroid disease, pancreatic disease, history of cancer within past 5 years (excluding basal cell carcinoma), anemia, or any other disease or condition which, in the Investigator's opinion, could interfere with the results of the study or the safety of the subject
• •5. Use of drugs or supplements to manage body weight or body fat in the last 3 months
• •6. Use of laxatives or fiber supplements in the past 6 weeks.
• •7. History of chronic active inflammatory disorders
• •8. History of bariatric surgery
• •9. History of any chronic gastrointestinal disease (e.g. IBD) or disorders (e.g. IBS, constipation, diarrhea), or gastrointestinal reflux disease
• •10. Regular use of non-steroidal anti-inflammatory drugs, systemic or inhaled corticosteroids, or systemic immunomodulatory drugs
• •11. Regular (more than once per week) use of proton pump inhibitors
• •12. Recent (last 3 months) or ongoing antibiotic use
• •13. Immunosuppression or ongoing therapy causing immunosuppression
• •14. Use of probiotic supplements during the previous 6 weeks
• •15. Significant change in tobacco, snuff, nicotine and e-cigarette use habits in the past 3 months or planned cessation of the use of these products during the trial
• •16. Use of vitamin D supplementation of ≥100 µg/day
• •17. Active or recent (last 3 months) participation in a weight loss program (diet and/or exercise)
• •18. Weight change (increase or loss) of 3 kg during the past 3 months
• •19. Pregnant or planning pregnancy during the study or breastfeeding
• •20. Participation in a clinical trial with an investigational product or drug within 60 days prior to screening
• •21. Likeliness to be noncompliant with the protocol
• •22. No possibility of contact in case of emergency
• •23. Illicit drug users
• •24. Alcohol abusers
• •25. Administrative or legal supervision
• •26. Subject who would receive more than 4500 euros as indemnities for his participation in biomedical research within the 12 last months, including the indemnities for the present study
• •27. Other reasons that, in the opinion of the Investigator, make the participant unsuitable for enrolment
• •28. Other reasons that, in the opinion of the Investigator, make the participant unsuitable for enrolment